BOLT Bolt Biotherapeutics: Forward P/S Multiple
High unmet demand for solid tumor therapies creates excellent prospects for Bolt Biotherapeutics (BOLT). The expected P/S trend illustrates the market valuation of the business, where 2.40 shows the current value of the metric. Bolt Biotherapeutics is implementing innovative ISAC-conjugates for immune activation, leveraging its own centers in the US and unique Boltbody technology to combat cancer.
Analytical breakdowns for boltbio.com (BOLT)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Bolt Biotherapeutics|BOLT - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio Bolt Biotherapeutics, Inc.|BOLT - Aggregate Debt Obligations|Debts to Book Capitalization Bolt Biotherapeutics|BOLT - Company Long-Term Debt|Company Short-Term Debts Bolt Biotherapeutics|Quick Liquidity boltbio.com
- business earnings and investment ratios data:
BOLT - Company Net Income|Future Profit Bolt Biotherapeutics|BOLT - Market Price to Net Income Ratio|Forward P/E Multiple Bolt Biotherapeutics, Inc.|BOLT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Bolt Biotherapeutics|BOLT - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Bolt Biotherapeutics|BOLT - Earnings per share for the trailing year|Quarterly EPS earnings growth boltbio.com|BOLT - Earnings growth in current year|Net earnings per share growth forecast for next year Bolt Biotherapeutics
- revenue and sales details:
Summary company analysis:Bolt Bio BOLT
The forward P/S reflects the market value of Bolt Biotherapeutics (BOLT) relative to expected revenue, allowing for the determination of the asset's overvaluation through the ratio of market capitalization to projected sales. By analyzing the forward P/S level, an investor assesses the scaling potential of the ISAC platform, where following high R&D expenditures, low variable costs of antibody biosynthesis can sharply reduce the multiple once the drug enters the market.
Who Bolt Biotherapeutics competes with
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA: Price-to-Projected Revenue Ratio|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio immunovant.com (IMVT)|Price-to-Projected Revenue Ratio Kiniksa|Price-to-Projected Revenue Ratio GRFS|Forward Price-to-Revenue Multiple ADPT (Adaptive Biotechnologies Corp)|Price to Expected Revenue Ratio CLDX|Aurinia Pharmaceuticals - Forward Price-to-Revenue Multiple|Forward Price to Sales BCRX|Vera Therapeutics - Forward P/S Multiple|DNTH: Price-to-Projected Revenue Ratio|PHVS: Forward P/S Multiple|ABCL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Tourmaline Bio, Inc.|Market Cap to Future Revenue Ratio precigen.com PGEN|Forward Price-to-Revenue Multiple PHAR (Pharming Group)|Price to Expected Revenue Ratio NKTR|Forward P/S Multiple UPB (Upstream Bio Corp)|Forward Price to Sales ZBIO|Immunome, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio gossamerbio.com|KalVista Pharmaceuticals, Inc. (KALV) - Price-to-Projected Revenue Ratio|Septerna, Inc. - Forward Price to Sales|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Forward P/S Multiple Savara Pharma|Price-to-Projected Revenue Ratio Rigel Pharmaceuticals (RIGL)|ANAB: Future Price to Revenue|Forward P/S Multiple ATXS (Astria Therapeutics, Inc.)|enGene Holdings Inc (ENGN) - Market Cap to Future Revenue Ratio|RAPT: Forward Price-to-Revenue Multiple|JBIO - Forward P/S Multiple|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|KYTX: Price to Expected Revenue Ratio|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|Cabaletta Bio Inc. (CABA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple VTYX|Forward Price-to-Revenue Multiple Theratechnologies, Inc THTX|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|Market Cap to Expected Sales Ratio eledon.com (ELDN)|Agenus Inc. - Forward P/S Multiple|CLYM: Price-to-Projected Revenue Ratio|Zura Bio Limited (ZURA) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio aTyr Pharmaceuticals (ATYR)|Price-to-Projected Revenue Ratio Adagene Inc|Price-to-Projected Revenue Ratio IMA|Forward Price-to-Revenue Multiple STTK (Shattuck Labs, Inc.)|Price to Expected Revenue Ratio EQ|Price-to-Projected Revenue Ratio Connect Biopharma Holdings Limited CNTB|IMUX (Immunic Therapeutics) - Future Price to Revenue|Atara Biotherapeutics Inc - Forward P/S Multiple|Forward Price to Sales IFRX (InflaRx N.V.)|XFOR: Forward P/S Multiple|Adicet Bio, Inc. (ACET) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Celularity Inc|INMB: Forward Price to Sales|Price-to-Projected Revenue Ratio Barinthus Biotherapeutics (BRNS)|Forward Price-to-Revenue Multiple kezarlifesciences.com KZR|Forward P/S Multiple SABS (SAB Biotherapeutics, Inc.)|Forward P/S Multiple Akari Therapeutics PLC AKTX|ENLV: Forward Price-to-Revenue Multiple|Forward Price to Sales QTTB (Q32 Bio Inc.)|GOVX: Forward P/S Multiple|EDSA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio iBio|Forward Price-to-Revenue Multiple Carisma Tx (CARM)|Price-to-Projected Revenue Ratio XTL Biopharmaceuticals, Ltd. (XTLB)|Forward Price-to-Revenue Multiple hcwbiologics.com HCWB|Aptevo Therapeutics Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple AIM ImmunoTech, Inc. AIM|ADTX - Price-to-Projected Revenue Ratio|GRI (GRI Bio Inc) - Market Cap to Projected Revenue|XRTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Vyome Therapeutics (HIND)|REVB (Revelation Biosciences) - Forward P/S Multiple|Price-to-Projected Revenue Ratio INDP|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|Allakos Inc - Price-to-Projected Revenue Ratio|HOOK: Forward Price-to-Revenue Multiple|IGM Biosciences, Inc. - Price to Expected Revenue Ratio|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Inc - Forward Price to Sales|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Price-to-Projected Revenue Ratio THRD
